Drug
Xanomeline Trospium Chloride
Xanomeline Trospium Chloride: highest development phase Post-Market, developed by Bristol-Myers Squibb, Karuna Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bristol-Myers Squibb, Karuna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Xanomeline/trospium chloride NCT07257120 | Post-Market | Healthy Volunteers |
| Xanomeline/trospium chloride NCT07221877 | Post-Market | Schizophrenia |
| Xanomeline/Trospium Chloride NCT07686263 | Phase 3 | Schizophrenia |
| Xanomeline/Trospium Chloride Capsule NCT07011732 | Phase 3 | Alzheimer Disease |
| Xanomeline/Trospium Chloride NCT07140913 | Phase 3 | Mania |
| Xanomeline/Trospium Chloride Capsule NCT07011745 | Phase 3 | Alzheimer's Disease |
| Xanomeline/Trospium Chloride NCT06729970 | Phase 1 | Healthy Volunteers |
| Xanomeline/ Trospium Chloride NCT07204418 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Xanomeline Trospium Chloride on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.